Three reasons why SIGA is in my portfolio

1) Monkeypox is in the early stages of a pandemic.

2) The Baseline Financials are Exceptional

3) Market Research Indicates TPOXX is the Only Viable Antiviral (so far)

“Taking note of government documents available in this article I wrote, it may be reasonable to infer that TPOXX has few competitors or potential competitors. This is only one piece of the equation, however. If all the drugs are sub-par (par being the level required for EUA, approval, and widespread public use), it doesn’t matter that TPOXX is better.”

https://investingpioneer.com/2022/08/12/three-reasons-why-siga-is-in-my-portfolio/